- Effective bioremediation of a comingled 1,1,1-TCA/TCE plume
- All chlorinated VOCs were below or near ROD specified limits within 18 months
- KB-1® Plus and electron donor applied in a single mobilization into an aerobic aquifer using anaerobic chase water
- Successful pilot study led to two full scale KB-1® Plus bioaugmentation implementations at the Site
- Client: GSI Water Solutions, Portland, Oregon
- Site Location: Oregon
- Services Provided:
- KB-1® Bioaugmentation
- Gene-Trac® Dehalococcoides and Dehalobacter testing
Three Site areas were impacted with 1,1,1-trichloroethane (1,1,1-TCA) and trichloroethene (TCE) associated with historical solvent use. Notably, 1,1,1-TCA is known to inhibit the reductive dechlorination of TCE if the requisite dechlorinating microorganisms are absent. Gene-Trac® testing indicated that dechlorinating Dehalococcoides (Dhc) and Dehalobacter (Dhb) microbes were absent prior to bioaugmentation. The Site groundwater was aerobic and not conducive to growth of dechlorinating microorganisms prior to enhanced in situ bioremediation (EISB). A pilot study was conducted to determine if: (1) EISB would promote degradation of TCE and 1,1,1-TCA below EPA Record of Decision (ROD) limits; and (2) would EISB reduce overall remediation costs.
The pilot study, initiated in June 2008, included 17 temporary injection points which were used to apply emulsified vegetable oil (EVO) and 1 liter of KB-1® Plus per point to introduce Dhc and Dhb microorganisms. Anaerobic water was injected before and after KB-1® Plus to limit the culture’s exposure to aerobic groundwater. This allowed the electron donor and KB-1® Plus to be applied in the same mobilization, minimizing application costs.
Within 8 months of KB-1® Plus bioaugmentation, 1,1,1-TCA and TCE concentrations decreased to below 5 µg/L in 4 of 6 monitoring wells. After 18 months, all chlorinated VOCs were below or near ROD limits. The pilot test was deemed sufficiently effective that full-scale application in this area was not required. Full-scale KB-1® Plus bioaugmentation was implemented at two other Site areas in 2009 and 2010.